Mereo BioPharma (MREO) Tax Provisions (2023 - 2025)

Mereo BioPharma (MREO) has 3 years of Tax Provisions data on file, last reported at $10.4 million in Q4 2025.

• On a quarterly basis, Tax Provisions fell 4.13% year-over-year to $10.4 million in Q4 2025; TTM through Mar 2026 was $10.4 million, a 4.13% decrease from a year earlier, with the FY2025 full-year figure at $10.4 million, down 4.13% from the prior year.
• Tax Provisions for Q4 2025 stood at $10.4 million, down from $10.9 million in the prior quarter.
• Over the last five years, Tax Provisions for MREO reached as high as $10.9 million in Q4 2024 and fell as low as $532000.0 in Q4 2023.
• Historically, Tax Provisions has averaged $7.3 million across 3 years, with a median of $10.4 million in 2025.
• Across the five-year window, Tax Provisions soared 1941.92% in 2024 and slipped 4.13% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $532000.0 in 2023, then surged by 1941.92% to $10.9 million in 2024, then dropped by 4.13% to $10.4 million in 2025.
• Per Business Quant data, the three most recent Tax Provisions figures were $10.4 million in Q4 2025, $10.9 million in Q4 2024, and $532000.0 in Q4 2023.